

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FOURTH QUARTER ENDED 31 JULY 2025⁽¹⁾**

| | INDIVIDUAL QUARTER | | CUMULATIVE QUARTER | |
|--|---------------------------|------------------|---------------------------|------------------|
| | 31.7.2025 | 31.7.2024 | 31.7.2025 | 31.7.2024 |
| | RM'000 | RM'000 | RM'000 | RM'000 |
| Revenue | 12,290 | 14,876 | 48,564 | 54,570 |
| Cost of sales | (5,127) | (8,723) | (26,201) | (31,899) |
| Gross profit | 7,163 | 6,153 | 22,363 | 22,671 |
| Other income | 311 | 383 | 1,450 | 1,561 |
| Marketing expenses | (401) | (387) | (1,308) | (1,145) |
| Administrative and other expenses | (3,520) | (2,322) | (11,587) | (10,310) |
| Finance costs | (8) | (31) | (67) | (136) |
| Profit before tax | 3,545 | 3,796 | 10,851 | 12,641 |
| Taxation | (1,036) | (758) | (2,587) | (3,344) |
| Profit for the financial period/year | 2,509 | 3,038 | 8,264 | 9,297 |
| Other comprehensive income, net of tax | - | - | - | - |
| Total comprehensive income | 2,509 | 3,038 | 8,264 | 9,297 |
| Profit attributable to: | | | | |
| Owners of the parent | 2,493 | 3,039 | 8,133 | 8,991 |
| Non-controlling interests | 16 | (1) | 131 | 306 |
| | 2,509 | 3,038 | 8,264 | 9,297 |
| Earnings per share attributable to owners of the parent ("EPS"): | | | | |
| Basic and diluted ⁽²⁾ (sen) | 0.67 | 0.81 | 2.18 | 2.40 |

Notes:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period/year under review.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2025⁽¹⁾

| | Unaudited as at 31 July 2025 RM'000 | Audited as at 31 July 2024 RM'000 |
|---|---|---|
| ASSETS | | |
| Non-current assets | | |
| Property, plant and equipment | 33,500 | 28,303 |
| Right-of-use assets | 4,638 | 4,689 |
| Deferred tax assets | 4 | - |
| Goodwill | 287 | 287 |
| Current assets | | |
| Inventories | 18,947 | 14,569 |
| Trade and other receivables | 15,017 | 20,131 |
| Marketable securities | 4,950 | 9,278 |
| Current tax assets | 2,257 | 1,219 |
| Derivative assets | - | - |
| Cash and bank balances | 11,617 | 4,232 |
| TOTAL ASSETS | 91,217 | 82,708 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| Share capital | 44,348 | 44,348 |
| Reserves | 35,770 | 27,637 |
| Equity attributable to owners of the parent | 80,118 | 71,985 |
| Non-controlling interest | 1,234 | 788 |
| TOTAL EQUITY | 81,352 | 72,773 |
| Non-current liabilities | | |
| Borrowings | - | 256 |
| Lease liabilities | 8 | - |
| Government grants | 2,165 | 2,503 |
| Deferred tax liabilities | 1,948 | 1,151 |
| Current liabilities | | |
| Trade and other payables | 5,225 | 4,445 |
| Borrowings | - | 606 |
| Lease liabilities | 40 | 14 |
| Government grants | 465 | 430 |
| Current tax liabilities | 14 | 530 |
| TOTAL LIABILITIES | 9,865 | 9,935 |
| TOTAL EQUITY AND LIABILITIES | 91,217 | 82,708 |

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2025⁽¹⁾ (cont'd)

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Financial Position is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FOURTH QUARTER ENDED 31 JULY 2025⁽¹⁾

| | Attributable to owners of the Parent | | | | | |
|--|--------------------------------------|-------------------------------|-------------------|---------------|--------------------------|---------------|
| | Non-distributable | | Distributable | | Non-controlling interest | Total equity |
| | Share capital | Reorganisati on debit reserve | Retained earnings | Total | | |
| | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 | RM'000 |
| Balance as at 1 August 2024 | 44,348 | (6,851) | 34,488 | 71,985 | 788 | 72,773 |
| Profit for the financial year | - | - | 8,133 | 8,133 | 131 | 8,264 |
| Other comprehensive income, net of tax | - | - | - | - | - | - |
| Total comprehensive income | - | - | 8,133 | 8,133 | 131 | 8,264 |
| <u>Transactions with owners</u> | | | | | | |
| - Dividend paid | - | - | - | - | (60) | (60) |
| - Ordinary shares | - | - | - | - | 375 | 375 |
| Total transaction with owners | - | - | - | - | 315 | 315 |
| Balance as at 31 July 2025 | 44,348 | (6,851) | 42,621 | 80,118 | 1,234 | 81,352 |

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Changes in Equity is disclosed in Note A1 and should be read in conjunction with the Group Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE FOURTH QUARTER ENDED 31 JULY 2025⁽¹⁾

| | 12-month ended 31 July 2025 RM'000 | 12-month ended 31 July 2024 RM'000 |
|---|--|--|
| CASH FLOWS FROM OPERATING ACTIVITIES | | |
| Profit before tax | 10,851 | 12,641 |
| Adjustments for: | | |
| Depreciation of property, plant and equipment | 2,844 | 2,369 |
| Depreciation of right-of-use assets | 124 | 129 |
| Amortisation of government grants | (370) | (370) |
| Finance costs | 67 | 136 |
| Interest income | (317) | (202) |
| Distribution income from short-term fund | (222) | (373) |
| Property, plant and equipment written off | - | 4 |
| Realised gain on fair value adjustment on marketable securities | - | - |
| Allowance of impairment losses on trade receivables | 201 | 26 |
| Unrealised loss/(gain) on foreign exchange | 134 | (58) |
| Fair value loss on derivative asset | - | 6 |
| Operating profit before changes in working capital | 13,312 | 14,308 |
| Increase in inventories | (4,378) | (2,055) |
| Decrease/(increase) in trade and other receivables | 4,949 | (7,358) |
| Increase in trade and other payables | 583 | 1,875 |
| Cash generated from operations | 14,466 | 6,770 |
| Government grants received | 67 | 60 |
| Interest received | 317 | 202 |
| Tax paid | (3,408) | (2,887) |
| Tax refunded | 60 | 179 |
| Net cash from operating activities | 11,502 | 4,324 |
| CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Purchase of marketable securities | (4,500) | (5,150) |
| Purchase of property, plant and equipment | (8,041) | (6,306) |
| Proceeds from disposal of marketable securities | 9,050 | 8,119 |
| Net cash used in investing activities | (3,491) | (3,337) |

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FOURTH QUARTER ENDED 31 JULY 2025⁽¹⁾ (Cont'd)

| | 12-month ended 31 July 2025 RM'000 | 12-month ended 31 July 2024 RM'000 |
|---|--|--|
| CASH FLOWS FROM FINANCING ACTIVITIES | | |
| Capital contribution of non-controlling interest ⁽²⁾ | 375 | * |
| Dividend paid to non-controlling interest | (60) | - |
| Drawdown of bankers' acceptance | - | - |
| Repayment of bankers' acceptance | - | - |
| Repayment of term loans | (862) | (2,726) |
| Interest paid | (66) | (135) |
| Payment of lease liabilities | (40) | (46) |
| Net cash used in financing activities | (653) | (2,907) |
| Net increase/(decrease) in cash and cash equivalents | 7,358 | (1,920) |
| Effect of foreign exchange rates changes | 27 | 45 |
| Cash and cash equivalents at beginning of financial years | 4,232 | 6,107 |
| Cash and cash equivalents at end of financial years | 11,617 | 4,232 |

Notes:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Cash Flows is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.
- (2) There is capital contribution of non-controlling interest amounting to RM130 for financial year ended 31 July 2024.

(The remaining of this page is intentionally left blank)

A. NOTES TO THE INTERIM FINANCIAL REPORT

A1. Basis of preparation

The interim financial report of UMediC Group Berhad (“**UMC**” or the “**Company**”) and its subsidiaries (collectively, the “**Group**”) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“**MFRS**”) 134, Interim Financial Reporting issued by the Malaysian Accounting Standards Board (“**MASB**”) and Paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad (“Listing Requirements”).

This interim financial report should be read in conjunction with the Group’s Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

A2. Significant Accounting Policies

The significant accounting policies and methods of computation applied in the unaudited condensed financial statements are consistent with those adopted in audited financial statements for the financial year ended 31 July 2024, except for the adoption of the following MFRSs and Amendment to MFRSs and Interpretation.

(a) New MFRSs adopted during the financial period

The Group and the Company adopted the following Standards and Amendments to Standards of the MFRS Framework that were issued by the MASB during the financial periods:

| Title | Effective Date |
|--|-----------------------|
| Amendments to MFRS 16 Lease Liability in a Sale and Leaseback | 1 January 2024 |
| Amendments to MFRS 101 Classification of Liabilities as <i>Current or Non-current</i> | 1 January 2024 |
| Amendments to MFRS 101 Non-current Liabilities with Covenants | 1 January 2024 |
| Amendments to MFRS 107 and MFRS 7 Supplier Finance <i>Arrangements</i> | 1 January 2024 |

Adoption of the above Standards and Amendments to Standards did not have any material effect on the financial performance or position of the Group and of the Company during the financial year.

(b) New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2025

The following are Standards and Amendments to Standards of the MFRS Framework that have been issued by the MASB but have not been early adopted by the Group and the Company:

| Title | Effective Date |
|---|-----------------------|
| Amendments to MFRS 121 <i>Lack of Exchangeability</i> | 1 January 2025 |
| Amendments to MFRS 9 and MFRS 7 <i>Amendments to the Classification and Measurement of Financial Instruments</i> | 1 January 2026 |
| <i>Annual Improvements to MFRS Accounting Standards – Volume 11</i> | 1 January 2026 |
| Amendments to MFRS 9 and MFRS 7 <i>Contracts Referencing Nature-dependent Electricity</i> | 1 January 2026 |
| MFRS 18 <i>Presentation and Disclosure in Financial Statements</i> | 1 January 2027 |
| MFRS 19 <i>Subsidiaries without Public Accountability: Disclosures</i> | 1 January 2027 |
| Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i> | Deferred |

The Group and the Company are in the process of assessing the impact of implementing these Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

A3. Auditors' Report

There was no qualification on the audited financial statements of the Group for the financial year ended 31 July 2024.

A4. Seasonal or Cyclical Factors

The business operations of the Group were not affected by any seasonal or cyclical trend during the current quarter and financial year under review.

A5. Material Unusual Items

There were no unusual items affecting the assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial year under review.

A6. Material Changes in Estimates

There were no changes in estimates that have a material effect in the current quarter and financial year under review.

A7. Debt and Equity Securities

There was no issuance, cancellation, repurchase, resale and repayment of debts and equity securities during the current quarter and financial year under review.

A8. Dividend Paid

No dividend was paid during the current quarter.

A9. Segmental Information

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all its products. The Group is also involved in developing, manufacturing and marketing of its medical consumables.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

- (a) Marketing and distribution – marketing and distribution of medical devices as well as the provision of after-sales service; and
- (b) Manufacturing – developing, manufacturing and marketing of medical consumables.

The Group's segmental information for the financial year under review is as follows:

| 31 July 2025 | Manufacturing | Marketing and distribution | Eliminations | Consolidated |
|--|---------------|----------------------------|--------------|--------------|
| | RM'000 | RM'000 | RM'000 | RM'000 |
| Results | | | | |
| Revenue from external customers | 16,366 | 32,198 | - | 48,564 |
| Inter-segment revenue | 3,134 | 646 | (3,780) | - |
| Total revenue | 19,500 | 32,844 | (3,780) | 48,564 |
| Interest income and distribution income from short-term fund | 216 | 323 | - | 539 |
| Interest expense | (20) | (60) | 13 | (67) |
| Net Interest income | 196 | 263 | 13 | 472 |
| Segment profit before tax | 3,667 | 5,015 | 2,169 | 10,851 |

A10. Material Events Subsequent to the end of the Quarter

There were no other material events subsequent to the end of the current quarter and financial year under review that have not been reflected in this interim financial report.

A11. Changes in the Composition of the Group

On 10 October 2024, UMC subscribed an additional 674,100 new ordinary shares in Ateria Medika Sdn. Bhd. ("Ateria") at an issue price of RM1.00 per share, for a cash consideration of RM674,100 ("Subscription").

Upon completion of the Subscription, Ateria is now a 90%-owned subsidiary of UMC.

On 18 December 2024, UMC subscribed an additional 349,930 new ordinary shares in Akiteck (Malaysia) Sdn. Bhd. ("Akiteck") at an issue price of RM1.00 per share, for a cash consideration of RM349,930 ("Subscription").

Upon completion of the Subscription, Akiteck is now a 70%-owned subsidiary of UMC.

On 11 March 2025, UMC had incorporated a 85% owned new subsidiary known as Rescue Medic Sdn. Bhd. ("Rescue Medic") with paid-up share capital of RM1,000 comprising 1,000 ordinary shares. The intended principal activities of Rescue Medic are marketing and distribution of medical devices as well as the provision of after-sales service, healthcare and other related services.

On 30 May 2025, UMC subscribed an additional 849,150 new ordinary shares in Rescue Medic at an issue price of RM1.00 per share, for a cash consideration of RM849,150 ("Subscription").

Upon completion of the Acquisition and the Subscription, Rescue Medic is now a 85%-owned subsidiary of UMC.

Apart from the above, there were no changes in the composition of the Group during the current quarter and financial year under review.

A12. Contingent Liabilities and Contingent Assets

There were no material contingent liabilities or contingent assets as at the date of this interim financial report.

A13. Material Capital Commitment

Save as disclosed below, as at 31 July 2025, the Group does not have any other material capital commitment:

| | RM'000 |
|---|---------------|
| Capital expenditure in respect of purchase of property, plant and equipment | |
| - Approved and contracted for | 6,890 |
| - Approved but not contracted for | - |
| Total | 6,890 |
| | |

A14. Significant Related Party Transactions

There were no significant related party transactions during the current quarter.

A15. Derivative Financial Instruments

As at 31 July 2025, the Group does not have any derivatives financial instruments.

A16. Fair Value of Financial Liabilities

There were no gains or losses arising from fair value changes of the Group's financial liabilities for the current quarter and financial year under review.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS

B1. Review of Performance

| | Individual Quarter 3-months ended | | Cumulative Quarter 12-months ended | |
|---|-----------------------------------|--------------------------|------------------------------------|--------------------------|
| | 31 July 2025 (RM'000) | 31 July 2024 (RM'000) | 31 July 2025 (RM'000) | 31 July 2024 (RM'000) |
| Revenue | 12,290 | 14,876 | 48,564 | 54,570 |
| Profit before tax ("PBT") | 3,545 | 3,796 | 10,851 | 12,641 |
| Profit for the financial period/year | 2,509 | 3,038 | 8,264 | 9,297 |
| Profit attributable to owners of the parent | 2,493 | 3,039 | 8,133 | 8,991 |

The Group's revenue decreased by approximately RM 2.59 million or 17.38% from approximately RM14.88 million achieved in the corresponding quarter of the previous financial year to approximately RM12.29 million in the current quarter.

The PBT of the Group decreased by approximately RM0.25 million or 6.61% from approximately RM3.79 million in the corresponding quarter of the previous financial year to approximately RM3.54 million in the current quarter.

The decrease in revenue and PBT in the current quarter as compared to the corresponding quarter was contributed by both the marketing and distribution and manufacturing segments. The decrease was mainly due to a lower demand for medical devices and consumables from both public and private hospitals as well as healthcare service providers.

B2. Comparison with Immediate Preceding Quarter

| | Individual Quarter 3-months ended | | | |
|---|-----------------------------------|---------------------------|-------------|-------|
| | 31 July 2025 (RM'000) | 30 April 2025 (RM'000) | Differences | |
| | | | RM'000 | % |
| Revenue | 12,290 | 11,640 | 650 | 5.58 |
| PBT | 3,545 | 2,412 | 1,133 | 46.97 |
| Profit for the financial period | 2,509 | 1,935 | 574 | 29.66 |
| Profit attributable to owners of the parent | 2,493 | 1,904 | 589 | 30.93 |

The Group's revenue increased by approximately RM0.65 million or 5.58% from approximately RM11.64 million achieved in the immediate preceding quarter to approximately RM12.29 million in the current quarter. The increase in revenue was contributed by both the marketing and distribution and manufacturing segments.

The Group's PBT increased by approximately RM1.13 million or 46.97% from approximately RM2.41 million achieved in the immediate preceding quarter to approximately RM3.54 million in the current quarter.

B3. Prospects

Given the Malaysian government's sustained commitment towards advancing the nation's healthcare standards, UMC remains optimistic about its future growth trajectory driven by key factors such as the increasing demand for healthcare facility upgrades, healthcare tourism as well as the immense need to address facility overcrowding, enabling the Group to further solidify its pivotal role within the ever-evolving healthcare landscape.

Aligned with that, the government allocated RM45.3 billion to Ministry of Health under Budget 2025 which represented a 10.0% increase over the preceding year's RM41.2 billion. This makes it the second largest budget allocation which is a testament of the government's resolute emphasis in delivering quality healthcare, underscoring the growing importance of both the public and private healthcare sectors. Paired along with the government's plan to allocate RM40.0 billion towards the healthcare sector from 2026 to 2030 under the 13th Malaysia Plan (13MP), this will bode well for the Group's outlook, focusing on core addressable area such as expanding access to medical services, upgrading public health facilities, and driving digital transformation.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B3. Prospects (Cont'd)

Building upon its established presence within the medical device sector, UMC has strategically undertaken a series of key initiatives to further elevate its market position within the broader healthcare industry. These strategic developments include the expansion into the laboratory segment to penetrate new addressable markets along with the incorporation of subsidiaries under Akiteck and Ateria to venture into medical moulding solutions as well as the import and export of medical devices. To broaden its horizons, the Group has expanded its offerings to include the provision of ambulance vehicles and services, healthcare care centre along with the establishment of a learning centre. Concurrently, within its manufacturing division, UMC is actively undertaking its next expansionary phase through the integration of advanced manufacturing technologies and expansion of its clean room facility to cater to the growing demand globally.

Given the several strategic initiatives undertaken by the Group, it believes that it is well poised for growth and aims to meet the anticipated growing demand to further enhance its overall presence within the medical industry. The Group can further enhance its overall presence in the medical industry by upholding the strategic initiatives.

B4. Profit Forecast

The Group did not issue any profit estimate, forecast, projection or internal targets in any public document.

B5. Taxation

The Group's taxation together with the comparison between the effective and statutory tax rates for the current quarter and financial period/year under review are as follows:

| | INDIVIDUAL QUARTER | | CUMULATIVE QUARTER | |
|--|---|---|--|--|
| | 3-month ended 31 July 2025 RM'000 | 3-month ended 31 July 2024 RM'000 | 12-month ended 31 July 2025 RM'000 | 12-month ended 31 July 2024 RM'000 |
| Income tax | | | | |
| Current tax expenses based on profit for the financial period/year | 559 | 668 | 1,869 | 2,461 |
| (Over)/under provision of tax expense in prior year | (3) | (8) | (75) | 39 |
| Deferred tax | | | | |
| Relating to origination and reversal of temporary differences | 480 | 16 | 793 | 762 |
| Under/(over)provision in prior years | - | 82 | - | 82 |
| Overall tax expenses | 1,036 | 758 | 2,587 | 3,344 |
| Effective tax rate (%) | 29.22 | 19.97 | 23.84 | 26.45 |
| Statutory tax rate (%) | 24.00 | 24.00 | 24.00 | 24.00 |

The Group's effective tax rate was at 23.84% for current financial year. The effective tax rate for current financial year was lower than the statutory tax rate of 24.00% mainly due to:

- (i) tax incentive enjoyed by its wholly-owned subsidiary, UWHM Sdn Bhd. UWHM Sdn Bhd is entitled to reinvestment allowance incentives under Schedule 7A, Income Tax Act 1967 for qualifying capital expenditure on the acquisition of machinery and equipment and;
- (ii) amortisation of grants, which was not subject to income tax.

B6. Status of Corporate Proposals

There were no corporate proposals announced and not completed as at the date of this interim financial report.

B7. Utilisation of Proceeds from the IPO

The gross proceeds from the IPO amounting to RM31.11 million excise in July 2022. On 5 June 2025, the Company announced the variation and extension of time for the Company's utilisation of the above proceeds up to 4 December 2025. Details of the utilisation is expected to be utilised in the following manner:

| Details of the use of proceeds | Estimated timeframe for the use of proceeds upon listing ⁽¹⁾ | Revised timeframe for utilisation ⁽²⁾ | Proposed Utilisation RM'000 | Allocation of IPO Proceeds upon listing (revised) RM'000 | Actual Utilisation RM'000 | Percentage utilised % |
|--|---|--|-----------------------------|--|---------------------------|-----------------------|
| Capital expenditure | | | | | | |
| (i) Construction of new factory building | Within thirty (30) months | | 3,500 | 3,500 | 3,500 ⁽³⁾ | 100.00 |
| (ii) Setting up new marketing and distribution offices | Within thirty-six (36) months | | 6,800 | - | - | - |
| (iii) Purchase of machinery and system, and expansion of cleanroom | | Within six (6) months | - | 5,500 | 467 | 8.49 |
| | | | 10,300 | 9,000 | 3,967 | 44.08 |
| Repayment of bank borrowings ⁽⁴⁾ | Within six (6) months | Within six (6) months | 9,000 | 9,300 | 9,300 | 100.00 |
| Working capital | Within thirty-six (36) months | Within six (6) months | 8,662 | 9,662 | 9,662 | 100.00 |
| Estimated listing expenses | Within two (2) months | | 3,150 | 3,150 | 3,150 | 100.00 |
| Total | | | 31,112 | 31,112 | 26,079 | |
| | | | | | | |

Notes:

- (1) From the date of listing of the Company on the ACE Market of Bursa Securities on 26 July 2022.
- (2) From the date of this announcement on 5 June 2025.
- (3) As stated in Section 3.7.1(i) of the Prospectus, the excess amount of approximately RM0.17 million has been used for working capital purposes.
- (4) Including lease liabilities owing to financial institutions.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B8. Group Borrowings and Debt Securities

The details of the Group's borrowings are as follows:

| | 12-month ended 31 July 2025 RM'000 | Audited as at 31 July 2024 RM'000 |
|--------------------------------|--|---|
| Current liabilities | | |
| Term loan | - | 606 |
| Bankers' acceptance | - | - |
| | - | 606 |
| Non-current liabilities | | |
| Term loan | - | 256 |
| | - | 256 |
| Total borrowings | - | 862 |

All the Group's borrowings are denominated in RM, secured and interest-bearing.

B9. Material Litigation

As at the date of this interim financial report, the Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, and the Directors are not aware of any proceedings pending or threatened against the Group, which may materially and adversely affect the financial position or business performance of the Group.

B10. Dividend

No dividend has been declared or recommended for the current quarter ended 31 July 2025.

B11. Earnings Per Share

The basic and diluted EPS for the current quarter and financial period/year are computed as follows:

| | 3-month ended 31 July 2025 | 3-month ended 31 July 2024 | 12-month ended 31 July 2025 | 12-month ended 31 July 2024 |
|--|----------------------------------|----------------------------------|-----------------------------------|-----------------------------------|
| Profit attributable to the owners of the parent (RM'000) | 2,493 | 3,039 | 8,133 | 8,991 |
| Number of ordinary shares (unit) ('000) | 373,910 | 373,910 | 373,910 | 373,910 |
| Basic EPS ⁽¹⁾ (sen) | 0.67 | 0.81 | 2.18 | 2.40 |
| Diluted EPS ⁽²⁾ (sen) | 0.67 | 0.81 | 2.18 | 2.40 |

Notes:

- (1) Basic EPS is calculated by dividing the profit attributable to owners of the parent by the number of ordinary shares outstanding during the financial period/year under review.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period/year under review.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)
(The remaining of this page is intentionally left blank)

B.12 Profit Before Tax

Profit before tax is arrived at after charging/(crediting):

| | 12-month ended 31 July 2025 | 12-month ended 31 July 2024 |
|---|--|--|
| | RM'000 | RM'000 |
| Depreciation of property, plant and equipment | 2,844 | 2,369 |
| Depreciation of right-of-use assets | 124 | 129 |
| Amortisation of government grants | (370) | (370) |
| Finance costs | 67 | 136 |
| Interest income | (317) | (202) |
| Distribution income from short-term fund | (222) | (373) |
| Property, plant and equipment written off | - | 4 |
| Realised gain on fair value adjustment on marketable securities | - | - |
| Allowance of impairment losses on trade receivables | 201 | 26 |
| Unrealised loss/(gain) on foreign exchange | 134 | (58) |
| Fair value loss on derivative asset | - | 6 |

Notes:

Save as disclosed above, the other disclosure items pursuant to Note 16, of Appendix 9B of the Listing Requirements are not applicable.

BY ORDER OF THE BOARD
11 September 2025